Charles S. Berkman - 01 Nov 2022 Form 4 Insider Report for OmniAb Operations, Inc.

Role
CLO & Secretary, Director
Signature
/s/ Charles S. Berkman
Issuer symbol
N/A
Transactions as of
01 Nov 2022
Net transactions value
$0
Form type
4
Filing time
03 Nov 2022, 21:08:45 UTC
Previous filing
30 Sep 2022
Next filing
05 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction Common Stock Award $0 +15,409 +41% $0.000000 52,587 01 Nov 2022 Direct F1, F2, F3
transaction Common Stock Disposed to Issuer -52,587 -100% 0 01 Nov 2022 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction Stock Option Award $0 +35,810 $0.000000 35,810 01 Nov 2022 Common Stock 35,810 $50.96 Direct F5
transaction Stock Option Disposed to Issuer -35,810 -100% 0 01 Nov 2022 Common Stock 35,810 $50.96 Direct F4, F5
transaction Stock Option Disposed to Issuer -1,701 -100% 0 01 Nov 2022 Common Stock 1,701 $31.62 Direct F3, F4, F6
transaction Stock Option Disposed to Issuer -3,627 -100% 0 01 Nov 2022 Common Stock 3,627 $48.21 Direct F3, F4, F6
transaction Stock Option Disposed to Issuer -5,966 -100% 0 01 Nov 2022 Common Stock 5,966 $56.41 Direct F3, F4, F6
transaction Stock Option Disposed to Issuer -8,117 -100% 0 01 Nov 2022 Common Stock 8,117 $89.36 Direct F3, F4, F6
transaction Stock Option Disposed to Issuer -12,797 -100% 0 01 Nov 2022 Common Stock 12,797 $66.30 Direct F3, F4, F7
transaction Stock Option Disposed to Issuer -15,043 -100% 0 01 Nov 2022 Common Stock 15,043 $53.77 Direct F3, F4, F8
transaction Stock Option Disposed to Issuer -6,076 -100% 0 01 Nov 2022 Common Stock 6,076 $99.75 Direct F3, F4, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Charles S. Berkman is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Includes 9,564 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire.
F2 Includes 26,789 shares of the Issuer's Common Stock received by the Reporting Person in connection with a pro-rata distribution in-kind from Ligand Pharmaceuticals Incorporated, which was exempt from reporting pursuant to Rule 16a-9.
F3 Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022.
F4 Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement.
F5 The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.
F6 The stock option is fully vested and exercisable.
F7 The stock option vests and is exercisable as to 12.5% of the underlying shares on August 11, 2019, and in 42 substantially equal monthly installments thereafter.
F8 The stock option vests and is exercisable as to 12.5% of the underlying shares on August 13, 2020, and in 42 substantially equal monthly installments thereafter.
F9 The stock option vests and is exercisable as to 12.5% of the underlying shares on August 3, 2021, and in 42 substantially equal monthly installments thereafter.